Lista de obras - Paola Storti - Dominio Público Uruguay

Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma

artículo científico publicado en 2020

Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients

scientific article published on 06 March 2019

Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma.

artículo científico publicado en 2017

Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma

artículo científico

Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients

artículo científico publicado en 2010

CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions.

artículo científico publicado en 2008

Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?

artículo científico publicado en 2016

Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target.

artículo científico publicado en 2016

Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease.

artículo científico publicado en 2009

Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo

artículo científico publicado en 2016

HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients.

artículo científico publicado en 2010

Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction.

artículo científico publicado en 2013

IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts.

artículo científico publicado en 2017

ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma

artículo científico publicado en 2017

Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules

artículo científico publicado en 2012

Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation.

artículo científico publicado en 2012

Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma.

artículo científico publicado en 2010

Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties

artículo científico publicado en 2017

Loss of Stromal Galectin-1 Enhances Multiple Myeloma Development: Emphasis on a Role in Osteoclasts

article

Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138+ cells

artículo científico publicado en 2010

Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability

artículo científico publicado en 2020

Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.

artículo científico publicado en 2012

Neurofibromatosis type I and multiple myeloma coexistence: A possible link?

artículo científico publicado en 2018

Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies

artículo científico publicado en 2020

Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations

article

PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression

artículo científico publicado en 2021

Possible targets to treat myeloma-related osteoclastogenesis.

artículo científico publicado en 2018

Role of Galectins in Multiple Myeloma

artículo científico publicado en 2017

Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome

artículo científico publicado en 2015

The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.

artículo científico publicado en 2015

The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.

artículo científico publicado en 2010

The transcriptomic profile of CD138+ cells from patients with early progression from smoldering to active multiple myeloma remains substantially unchanged

artículo científico publicado en 2019

Lista de obras de Paola Storti

Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma

Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients

Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma.

Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma

Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients

CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions.

Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?

Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target.

Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease.

Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo

HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients.

Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction.

IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts.

ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma

Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules

Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation.

Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma.

Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties

Loss of Stromal Galectin-1 Enhances Multiple Myeloma Development: Emphasis on a Role in Osteoclasts

Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138+ cells

Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability

Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.

Neurofibromatosis type I and multiple myeloma coexistence: A possible link?

Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies

Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations

PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression

Possible targets to treat myeloma-related osteoclastogenesis.

Role of Galectins in Multiple Myeloma

Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome

The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.

The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.

The transcriptomic profile of CD138+ cells from patients with early progression from smoldering to active multiple myeloma remains substantially unchanged